Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $4.50 Average PT from Analysts

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has earned an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $4.50.

A number of equities research analysts have recently issued reports on SGMO shares. Barclays cut their target price on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 14th. Wall Street Zen raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, June 24th.

Institutional Trading of Sangamo Therapeutics

A number of hedge funds have recently modified their holdings of the company. Wasatch Advisors LP lifted its position in shares of Sangamo Therapeutics by 17.7% in the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock worth $4,376,000 after acquiring an additional 1,215,653 shares during the period. Geode Capital Management LLC raised its holdings in shares of Sangamo Therapeutics by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,332,279 shares of the biopharmaceutical company’s stock worth $1,263,000 after buying an additional 48,829 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Sangamo Therapeutics in the 4th quarter worth approximately $2,316,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Sangamo Therapeutics in the 4th quarter worth approximately $1,744,000. Finally, Jacobs Levy Equity Management Inc. raised its holdings in shares of Sangamo Therapeutics by 74.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company’s stock worth $851,000 after buying an additional 555,323 shares in the last quarter. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock opened at $0.58 on Wednesday. Sangamo Therapeutics has a 1 year low of $0.41 and a 1 year high of $3.18. The stock has a fifty day moving average of $0.52 and a two-hundred day moving average of $0.71. The firm has a market capitalization of $174.99 million, a PE ratio of -2.00 and a beta of 1.18.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $18.31 million during the quarter, compared to analyst estimates of $31.68 million. Sangamo Therapeutics had a negative net margin of 77.48% and a negative return on equity of 293.05%. Equities research analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.